Citi downgraded Schrodinger (SDGR) to Neutral from Buy with a price target of $20, down from $35. The firm cites the recent developments in the company’s internally developed drug pipeline as well as continued headwinds facing the biotech and pharma industries, the analyst tells investors in a research note. Citi adds that its positive stance was largely based on the three shots on goal the company had in its early stage Phase 1 assets to highlight how its drug development platform could discover novel targets that biopharma partners would be interested in, but to date, Schrodinger’s recent updates have fallen short, raising concerns on the potential of the company’s proprietary drug portfolio efforts.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Schrodinger’s Hold Rating: Challenges in Drug Pipeline and Software Growth Amid Macroeconomic Headwinds
- Schrodinger discontinues SGR-2921 clinical development program
- Schrodinger initiated with an Overweight at Barclays
- Schrodinger’s Strong Financial Performance and Promising Pipeline Developments Justify Buy Rating
- Schrodinger’s Strategic Growth and Financial Stability: Buy Rating Affirmed